Biogen Statistics

Total Valuation

Biogen has a market cap or net worth of EUR 22.60 billion. The enterprise value is 24.66 billion.

Market Cap	22.60B
Enterprise Value	24.66B

Important Dates

The next confirmed earnings date is Wednesday, April 29, 2026.

Earnings Date	Apr 29, 2026
Ex-Dividend Date	n/a

Share Statistics

Current Share Class	146.76M
Shares Outstanding	n/a
Shares Change (YoY)	+0.82%
Shares Change (QoQ)	-0.27%
Owned by Insiders (%)	0.20%
Owned by Institutions (%)	96.45%
Float	146.28M

Valuation Ratios

The trailing PE ratio is 20.52 and the forward PE ratio is 11.66.

PE Ratio	20.52
Forward PE	11.66
PS Ratio	2.68
PB Ratio	1.45
P/TBV Ratio	10.26
P/FCF Ratio	12.94
P/OCF Ratio	12.04
PEG Ratio	n/a

Enterprise Valuation

The stock's EV/EBITDA ratio is 7.76, with an EV/FCF ratio of 14.12.

EV / Earnings	22.39
EV / Sales	2.92
EV / EBITDA	7.76
EV / EBIT	10.24
EV / FCF	14.12

Financial Position

The company has a current ratio of 2.68, with a Debt / Equity ratio of 0.36.

Current Ratio	2.68
Quick Ratio	1.70
Debt / Equity	0.36
Debt / EBITDA	1.79
Debt / FCF	3.25
Interest Coverage	10.56

Financial Efficiency

Return on equity (ROE) is 7.39% and return on invested capital (ROIC) is 11.19%.

Return on Equity (ROE)	7.39%
Return on Assets (ROA)	6.14%
Return on Invested Capital (ROIC)	11.19%
Return on Capital Employed (ROCE)	10.82%
Weighted Average Cost of Capital (WACC)	n/a
Revenue Per Employee	1.12M
Profits Per Employee	146,822
Employee Count	7,500
Asset Turnover	0.34
Inventory Turnover	0.90

Taxes

In the past 12 months, Biogen has paid 224.51 million in taxes.

Income Tax	224.51M
Effective Tax Rate	16.94%

Stock Price Statistics

The stock price has increased by +49.71% in the last 52 weeks.

Beta (5Y)	n/a
52-Week Price Change	+49.71%
50-Day Moving Average	159.07
200-Day Moving Average	139.64
Relative Strength Index (RSI)	49.62
Average Volume (20 Days)	21

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	3.57

Income Statement

In the last 12 months, Biogen had revenue of EUR 8.42 billion and earned 1.10 billion in profits. Earnings per share was 7.49.

Revenue	8.42B
Gross Profit	6.65B
Operating Income	2.41B
Pretax Income	1.33B
Net Income	1.10B
EBITDA	3.07B
EBIT	2.41B
Earnings Per Share (EPS)	7.49

Balance Sheet

The company has 3.25 billion in cash and 5.67 billion in debt, giving a net cash position of -2.05 billion.

Cash & Cash Equivalents	3.25B
Total Debt	5.67B
Net Cash	-2.05B
Net Cash Per Share	n/a
Equity (Book Value)	15.55B
Book Value Per Share	105.92
Working Capital	4.79B

Cash Flow

In the last 12 months, operating cash flow was 1.88 billion and capital expenditures -130.99 million, giving a free cash flow of 1.75 billion.

Operating Cash Flow	1.88B
Capital Expenditures	-130.99M
Depreciation & Amortization	667.02M
Net Borrowing	-253.93M
Free Cash Flow	1.75B
FCF Per Share	n/a

Margins

Gross margin is 78.95%, with operating and profit margins of 28.55% and 13.07%.

Gross Margin	78.95%
Operating Margin	28.55%
Pretax Margin	15.74%
Profit Margin	13.07%
EBITDA Margin	36.44%
EBIT Margin	28.55%
FCF Margin	20.73%

Dividends & Yields

Biogen does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	-0.82%
Shareholder Yield	-0.82%
Earnings Yield	4.87%
FCF Yield	7.73%

Stock Splits

This stock does not have any record of stock splits.

Last Split Date	n/a
Split Type	n/a
Split Ratio	n/a

Scores

Biogen has an Altman Z-Score of 2.97 and a Piotroski F-Score of 6. A Z-score under 3 suggests an increased risk of bankruptcy.

Altman Z-Score	2.97
Piotroski F-Score	6